Dermatology Advisor

Deucravacitinib Is Effective for PsO Following Inadequate Response to Apremilast

Deucravacitinib in patients with plaque psoriasis who did not have adequate response to apremilast is effective and ...
Pharmabiz

Bristol Myers announces positive results from POETYK PSO-1 phase 3 study of deucravacitinib to treat severe psoriasis patients

Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
Nasdaq

Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study

Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
IGN

PSO-1 (4x)

The PSO-1 (Pritsel Snaipersky Optichesky, "Optical Sniper Sight") is a Russian scope with 4x magnification compared to the iron sights. The PSO-1 (4x) falls in the Optics Category of the Weapon ...